Yoshimasa Kosaka

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

Chemotherapy Versus Placebo, Breast Oncology, Oncology +7

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer

Jonathan T. Lei, Jieya Shao, Jin Zhang et al. · Cell Reports · 2018 · 106 citations · Full text

Tripartite Motif-Containing 29 (TRIM29) Is a Novel Marker for Lymph Node Metastasis in Gastric Cancer

Yoshimasa Kosaka, Hiroshi Inoue, Takahiro Ohmachi et al. · Annals of Surgical Oncology · 2007 · 104 citations

Oncology, Novel Marker, Medicine +9

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda et al. · Supportive Care in Cancer · 2015 · 99 citations · Full text

Clinical Significance of BMP7 in Human Colorectal Cancer

Kazuo Motoyama, Fumiaki Tanaka, Yoshimasa Kosaka et al. · Annals of Surgical Oncology · 2008 · 95 citations

Medicine, Pathology, Colorectal Cancer +6